Company intelligence
CN Bio
Generate human-specific efficacy and safety data with PhysioMimix® microphysiological systems.
About CN Bio
CN Bio is a leading Organ-on-a-chip (OOC) company that enables scientists to improve the accuracy and efficiency of preclinical drug discovery. Our PhysioMimix® Core microphysiological system, 3D-validated cells, consumable plates, and Contract Research Services facilitate the prediction of human responses to drug exposure, in the presence or absence of disease, so that new medicines can be brought to market more rapidly, cost-effectively and using fewer animals. Utilizing primary cells, our perfused single (Lung, Liver), and multi-organ (Gut/Liver, Lung/Liver) models recapitulate the microarchitecture, microenvironment, and function of their human counterparts in vitro. The approach provides a viable alternative to animal models where translatability to humans is predicted to be poor and for testing advanced drug modalities where human-specific targets and pathways are required. They generate physiologically relevant, human-translatable, mechanistic data that enables researchers to progress only the safest and most efficacious drugs into in vivo animal studies and be better prepared for clinical trials. Please follow us for regular updates. Let's change the game, together!
Verified activity
Signals from CN Bio
4 published signals
Legal & Regulatory
CN Bio notes that the EMA has announced a new voluntary data submission pilot designed to help regulators gain experience with New Approach Methodologies (NAMs), including microphysiological systems, organoids, and computational approaches.
Reported by CN Bio
Research & Knowledge
CN Bio published a new technology guide exploring how liver microphysiological systems can help researchers generate human-relevant insight, improve translational relevance, and reduce uncertainty in modern toxicology workflows.
Reported by CN Bio
Research & Knowledge
CN Bio published a newly published paper providing insight into how collaborative cross-platform evaluation studies for liver MPS can be designed and implemented.
Reported by CN Bio
Partnerships
CN Bio is part of an Innovate UK-funded project delivered in partnership with NC3Rs to support the UK Government's roadmap to reduce dedicated pharmacokinetic studies using dogs and non-human primates by 35% by 2030.
Reported by CN Bio